PolyPid Ltd. (PYPD)
NASDAQ: PYPD · Real-Time Price · USD
2.990
-0.070 (-2.29%)
Feb 21, 2025, 4:00 PM EST - Market closed
PolyPid Employees
As of December 31, 2023, PolyPid had 62 total employees, including 59 full-time and 3 part-time employees. The number of employees increased by 2 or 3.33% compared to the previous year.
Employees
62
Change (1Y)
2
Growth (1Y)
3.33%
Revenue / Employee
n/a
Profits / Employee
-$468,097
Market Cap
30.47M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
PYPD News
- 10 days ago - PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewsWire
- 23 days ago - PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 24 days ago - PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025 - GlobeNewsWire
- 2 months ago - Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday - Benzinga
- 2 months ago - PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million - GlobeNewsWire
- 2 months ago - PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy - GlobeNewsWire
- 3 months ago - PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance - GlobeNewsWire